Deutsche Bank AG Reduces Position in Bausch Health Cos Inc. $BHC

Key Points

• Deutsche Bank AG drastically reduced its stake in Bausch Health Cos Inc. by selling 2,099,217 shares, leaving it with just 30,494 shares valued at $197,000.
• Insider trading activity revealed that Director John Paulson bought 34,721,118 shares for approximately $312.49 million, significantly increasing his ownership of the company.
• Despite recent challenges, Bausch Health's stock received an upgrade from "hold" to "buy" by Wall Street analysts, indicating potential for future growth with an average target price of $9.00.

Deutsche Bank AG reduced its holdings in shares of Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 98.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 30,494 shares of the company's stock after selling 2,099,217 shares during the period. Deutsche Bank AG's holdings in Bausch Health Cos were worth $197,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Bausch Health Cos by 0.5% during the first quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock worth $76,152,000 after buying an additional 61,621 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Bausch Health Cos by 3.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,113,107 shares of the company's stock worth $25,089,000 after acquiring an additional 90,166 shares during the period. Compass Rose Asset Management LP grew its stake in shares of Bausch Health Cos by 366.7% in the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock valued at $16,926,000 after purchasing an additional 1,650,000 shares during the last quarter. Private Management Group Inc. increased its holdings in shares of Bausch Health Cos by 13.8% in the first quarter. Private Management Group Inc. now owns 1,439,426 shares of the company's stock valued at $9,313,000 after purchasing an additional 174,176 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Bausch Health Cos by 4.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,341,999 shares of the company's stock valued at $8,700,000 after purchasing an additional 57,963 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $9.00.

Insider Buying and Selling at Bausch Health Cos

In other Bausch Health Cos news, Director John Paulson bought 34,721,118 shares of the business's stock in a transaction on Thursday, August 14th. The stock was bought at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the transaction, the director owned 70,755,869 shares in the company, valued at approximately $636,802,821. The trade was a 96.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders acquired a total of 44,316,834 shares of company stock valued at $369,628,560 in the last three months. Company insiders own 19.97% of the company's stock.

Bausch Health Cos Price Performance

BHC traded down $0.30 on Wednesday, hitting $7.39. 780,119 shares of the company were exchanged, compared to its average volume of 2,680,306. Bausch Health Cos Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $9.85. The company has a debt-to-equity ratio of 141.90, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market capitalization of $2.73 billion, a P/E ratio of 28.40 and a beta of 0.48. The business's fifty day moving average is $6.78 and its 200 day moving average is $6.08.

Bausch Health Cos (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The firm had revenue of $2.57 billion for the quarter, compared to analysts' expectations of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.